title: Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
abstract: OBJECTIVE
  To describe, in a 7-year follow-up study, the use of infliximab in patients with refractory posterior uveitis and scleritis.
  
  
  METHODS
  A 7-year follow-up case series study was performed. Patients with posterior uveitis and scleritis refractory to conventional therapies (steroids and at least one immunosuppressive agent) were included. Three infliximab intravenous doses of 5 mg/kg were administered at weeks 0, 2, and 6. Further infusions were allowed in patients undergoing a relapse of the uveitis after initial remission. All patients were followed up for at least 8 months. We defined uveitis improvement as an increase in the best-corrected visual acuity or an objective and significant improvement in retinal exudates and/or haemorrhages, cystoid macular oedema (CME), and vitreous haze. Infliximab-related adverse events, final prednisone doses, and the number of immunosuppressive agents used were recorded. A descriptive analysis was performed.
  
  
  RESULTS
  A total of 11 patients (17 eyes were affected at baseline) were included, 63% were women, the mean age was 43+/-14 years, and the median follow-up was 80 months (p25-p75: 50-80). After infliximab treatment, six eyes maintained their basal visual acuity, nine eyes showed improvement, and two worsened (in the two patients diagnosed with choroiditis). Vitreous haze, active retinal vasculitis, and CME, but not chorioretinal lesions, improved in all patients. All patients tapered their daily steroid dose and the number of immunosuppressive agents. No infliximab-related adverse events were reported.
  
  
  CONCLUSIONS
  Infliximab could be an effective and safe treatment in patients with posterior uveitis and scleritis refractory to conventional therapy.
authors.affiliation: Rheumatology Unit, Hospital Clinico San Carlos, Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Lopez-Gonzalez
authors.forename: E
authors.initials: E
authors.lastname: Loza
authors.forename: J A
authors.initials: JA
authors.lastname: Jover
authors.forename: J M
authors.initials: JM
authors.lastname: Benitez Del Castillo
authors.forename: R
authors.initials: R
authors.lastname: Mendez
authors.forename: C
authors.initials: C
authors.lastname: Hernandez-Garcia
authors.forename: E
authors.initials: E
authors.lastname: Pato
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015423:Scleritis / Q000188:drug therapy / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab